Chardan Capital upgraded shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) from a neutral rating to a buy rating in a report released on Friday morning, Marketbeat reports. Chardan Capital currently has $140.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $60.00.
Other research analysts also recently issued reports about the company. Royal Bank Of Canada raised their price objective on Sage Therapeutics from $117.00 to $120.00 in a research note on Thursday, November 2nd. Canaccord Genuity dropped their price target on Sage Therapeutics from $110.00 to $81.00 and set a buy rating on the stock in a research report on Tuesday, September 12th. Stifel Nicolaus assumed coverage on Sage Therapeutics in a research report on Wednesday, August 9th. They issued a buy rating and a $104.00 price target on the stock. Cowen and Company reaffirmed a buy rating and issued a $100.00 price target on shares of Sage Therapeutics in a research report on Friday, August 4th. Finally, Needham & Company LLC set a $95.00 price objective on Sage Therapeutics and gave the stock a buy rating in a report on Friday, August 4th. Three equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. Sage Therapeutics presently has an average rating of Buy and a consensus price target of $99.86.
Shares of Sage Therapeutics (NASDAQ:SAGE) opened at $94.65 on Friday. Sage Therapeutics has a one year low of $44.55 and a one year high of $99.80.
Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.98) by $0.01. Sage Therapeutics’s quarterly revenue was up .0% compared to the same quarter last year. equities analysts anticipate that Sage Therapeutics will post -7.36 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Chardan Capital Upgrades Sage Therapeutics, Inc. (SAGE) to Buy” was first published by Transcript Daily and is owned by of Transcript Daily. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://transcriptdaily.com/2017/11/14/chardan-capital-upgrades-sage-therapeutics-inc-sage-to-buy.html.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Sage Therapeutics by 11.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 138 shares during the last quarter. Hershey Trust Co. bought a new stake in Sage Therapeutics in the third quarter valued at about $118,000. Oppenheimer Asset Management Inc. increased its holdings in Sage Therapeutics by 412.9% in the third quarter. Oppenheimer Asset Management Inc. now owns 1,944 shares of the biopharmaceutical company’s stock valued at $122,000 after purchasing an additional 1,565 shares during the last quarter. Turner Investments LLC bought a new stake in Sage Therapeutics in the second quarter valued at about $159,000. Finally, Dubuque Bank & Trust Co. bought a new stake in Sage Therapeutics in the second quarter valued at about $167,000.
About Sage Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.